Implantable access system for prolonged intrapleural immunotherapy.
We describe our experience using an implantable Port-A-Cath access system for intrapleural administration of gamma-interferon (gamma-IFN) in malignant mesothelioma patients. Twenty nine patients, with histologically proven malignant mesotheliomas were included in this study. To avoid complications the device was implanted in a subcutaneous pocket, and the catheter was connected via a tunnel. Also, a suction drain was installed in the pocket after placement. This procedure greatly reduced the high infection rate (64%) encountered with conventional open chest tubes. Patients' tolerance was excellent and maintenance minimal. In our opinion, the Port-A-Cath system is the most suitable device for intra-cavitary long-term therapy of malignant pleural effusions.
Driesen
P
P
Dept of Pulmonology, Hôpital de la Conception, Marseille, France.
Boutin
C
C
Viallat
J R
JR
Astoul
P H
PH
Vialette
J P
JP
Pasquier
J
J
D000368:Aged; D002408:Catheters, Indwelling / Q000009:adverse effects; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000008:administration & dosage*; D008297:Male; D008654:Mesothelioma / Q000628:therapy*; D008722:Methods; D008875:Middle Aged; D010994:Pleura; D010997:Pleural Neoplasms / Q000628:therapy*
D007371:Interferon-gamma